Leiden collaboration enhances drug discovery for membrane proteins


A joint effort between Leiden University’s Professor Ubbink’s lab and ZoBio’s Assay Development and Screening team has advanced fragment-based drug discovery targeting membrane proteins. Supported by a Dutch Research Council (NWO) AES grant, the project utilized protein-lipid nanodiscs to study how lipid composition affects small molecule interactions with the membrane enzyme CYP3A4.

Findings revealed that lipid types significantly influence off-target binding, underscoring the importance of lipid selection in drug screening. This research, published in Chemical Biology and Drug Design, offers valuable insights for developing therapeutics targeting complex membrane proteins

Read more here


  • LUMC opens dedicated CAR-T department

    Leiden University Medical Center (LUMC) has opened a dedicated department for CAR-T cell therapy, bringing care, research and expertise in this rapidly developing field together in one place. The new department, officially opened on 24 September, marks another step in…

  • VarmX recognised with two prestigious industry award nominations

    Leiden-based biotech company VarmX has received two industry award nominations recognising its scientific approach and strategic partnership with CSL. VarmX has been shortlisted for the 2026 Prix Galien USA “Best Startup” Award, which recognises early-stage companies developing novel therapeutic approaches.…